Glonghui, October 14th — BMO Capital has lowered Novo Nordisk's target price from $47 to $40, maintaining a "market perform" rating.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.